IN.PACTTM AdmiralTM** continues to demonstrate long-term clinical outcomes, even in patients considered to be at high risk of restenosis and repeat interventions.

 

  • 74.5% IN.PACT SFA Trial1
  • 58.0% IN.PACT Global ISR Cohort2
  • 67.3% IN.PACT Global Long Lesion Cohort2
  • 69.8% IN.PACT Global CTO Cohort2
dcb

Proven formulation

The IN.PACTTM AdmiralTM DCB** features a proprietary FreePac™ coating solution that allows for the release of drug into the tissue through the restenotic window.
IN.PACTTM AdmiralTM DCB** provides 180 days of drug in tissue.§3
graph inpact

We have extended our DCB range

Introducing new longer lengths to our IN.PACTTM AdmiralTM** Drug-Coated Balloon range, to give you more options for treatment of longer, complex lesions. 
Clinical performance
  • Highest primary patency91.1%8
  • Mean Lesion length 26cm
dcb-range

Watch Dr. Ehrin Armstrong speak about the benefits and clinical evidence to support IN.PACT™ Admiral™** as his DCB of choice.
More information (see more) Less information (see less)

Meet Robert Canterbury, who was diagnosed with peripheral artery disease (PAD), and see how IN.PACT Admiral DCB helped get him back on his feet.
More information (see more) Less information (see less)

One proven formulation, two platforms for SFA treatment.

With 0.035” and 0.018” guidewire compatibility.

Lifeline cardiovascular technical support

Worldwide technical support - 24/7

+ 1 763-514-4000

rs.cstechsupport@medtronic.com

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

*Third-party brands are trademarks of their respective owners.
** The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.
† Primary patency not assessed after three years.
‡ Data on file UC202013694cEE at Medtronic. https://europe.medtronic.com/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/pvh/going-long-dcb/DCB_landscape_revision.pdf
§ Data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.

References

1

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.

2

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.

3

FDA. PMA P140010: Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140010(opens new window). Accessed May 10, 2022.

4

FDA. PMA P190019: FDA Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190019(opens new window). Accessed May 10, 2022.

5

Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. January 1, 2014;83(1):132-140.

6

FDA. PMA P160049: FDA summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160049(opens new window). Accessed May 10, 2022.

7

Based on clinical data for drug-coated balloons indicated to treat long SFA lesions (>180 mm): compared to Lutonix™* IFU BAW1387400r3. Per Stellarex™* IFU P011966-B, Stellarex is not indicated to treat lesions longer than 180 mm. Definitions of patency and lesion length may vary for different studies.

8

The IN.PACT Global Study Long Lesion Imaging Cohort D. Scheinert Circulation 2018.